The best hair salons in Peoria area as voted on by readers
Journal Star readers were invited to choose their favorite beauty and health service providers for the 2024 Community's Choice Awards.
Here are the top three hair salons in the Peoria area as voted on by participants:
4609 N. Prospect Road, Suite 21, Peoria Heights
(309) 303-6445
beauty-bar-on-prospect.square.site
2302 W. Glen Ave., Peoria
(309) 691-2522
1200 W. Main St., Suite 16, Peoria
(309) 643-2950
j-bstudio.com
Previous reporting: This Peoria barbershop is expanding with a second location
solasalonstudios.com
More: The best real estate agents in Peoria as voted on by readers
This article originally appeared on Journal Star: Beauty Bar on Prospect voted best hair salon in Peoria area
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
CHAI AI: Expands GPU Cluster to Reach 1.4 exaFLOPS in Compute
PALO ALTO, Calif., June 11, 2025 /PRNewswire/ -- CHAI, a leader in social AI, is betting big on compute—announcing aggressive infrastructure scaling to fuel its next-generation AI models. Since 2023, the company has made strategic investments in high-performance computing clusters that now compete with leading AI labs and startups. Investing in Next-Gen AI Models In 2025, CHAI projects to allocate $20M to further expand its compute capacity—a bold move that solidifies its competitive edge in AI research and product innovation. This strategic investment reflects broader industry trends where firms are racing to secure computing resources amid growing demand for AI capabilities. CHAI's in-house kCluster now delivers 1.4 exaFLOPs of computing power by utilizing thousands of cutting-edge GPUs. This infrastructure outpaces most AI startups in compute capability and surpasses academic benchmarks, offering nearly 10x the power of Stanford's Sherlock HPC Cluster. Leveraging this massive infrastructure advantage, CHAI accelerates cutting-edge AI research and serves over 51,000 LLMs to users worldwide, enabling richer interactions and deeper personalization. Was CHAI the first AI Platform? CHAI was the first consumer AI product to reach 1 million users, leveraging the open-sourced LLM GPT-J, before ChatGPT or Llama. What is CHAI? CHAI is a social AI platform where users can create their own AI. Since its launch three years ago, CHAI has experienced significant growth, particularly among Gen Z users. Now, to support further growth and wider adoption, CHAI has redesigned its brand. Can you use CHAI AI in a browser? As of March 2025, no. CHAI is focused on delivering the most engaging social AI experience by hiring talented engineers to refine its app. While there are currently no plans for a web app, this may change in the future. Is CHAI AI safe? CHAI has implemented a range of safety features that allow users to engage in dynamic chats while encouraging them to stay within established guidelines. By building better AI, CHAI aims to enhance user value and experience. What makes CHAI special? CHAI is designed to be the most engaging social AI, delivering highly entertaining conversations. Many users rely on it to craft interactive stories and immersive experiences. Why do people love CHAI? CHAI employs advanced AI techniques to increase the entertainment value of its bots. Users chat with AI to write interactive novels and have engaging conversations, supported by a variety of genres that appeal to avid novel readers. Sometimes regarded as the best free AI chatbot, CHAI is paving its way to widespread adoption of conversational social AI for entertainment. Who is the founder? William Beauchamp is a 2x founder, first started building CHAI with his sister in Cambridge UK in 2020. After building the first AI chat platform they relocated to Palo Alto. Are they hiring? CHAI is a rapidly growing company that is known for paying very high salaries with an intense culture focused on delivering results and iterating quickly. Apply on CHAI's website. View original content to download multimedia: SOURCE Chai Research Corp Sign in to access your portfolio
Yahoo
18 hours ago
- Yahoo
Metal manufacturer to lay off nearly 150 in Lakeville, Shakopee, Plymouth
A Plymouth-based sheet metal fabricator and manufacturer of precision metal components will close all of its Minnesota facilities, including its Lakeville, Plymouth and Shakopee locations, laying off nearly 150 workers following failed efforts to put itself up for sale. J&E Companies will lay off 45 employees from its Lakeville site alone, including welders, machine operators, process engineers, plant managers, drivers and other job classifications. A letter to the Minnesota Department of Employment and Economic Development, dated June 2, indicated that the layoffs will take effect that same day 'due to financial difficulties and circumstances,' and that 'a potential sale of the business' had fallen through. The workers are non-unionized and do not have bumping rights, according to the company's letter, which is signed by a corporate adviser from Harney Partners. J&E Companies was founded more than 65 years ago and provided precision machining and fabrication services to the medical, aerospace, commercial and agricultural industries, according to its website. In 2022, it acquired R&B, a Wisconsin-based precision machining company with more than 100 employees. In all, the merged companies maintained six sites in Minnesota, Racine, Wis. and Reynosa, Mexico, with a combined total of 325 employees. A call to a company spokesperson was not immediately returned on Wednesday. Whitebridge Capital Partners announced Wednesday it is acquiring the major assets of R&B Grinding of Racine, which will be renamed RB Industrial Manufacturing LLC, 'in recognition of the full range of machining processes the company can provide from its 140,000 square foot facility,' reads a statement from Whitebridge, which specializes in distressed manufacturing companies. 'We're not involved in the Minnesota operations at all,' said Todd DiBenedetto, principal with Whitebridge Capital Partners, in a brief phone interview on Wednesday. He said the Mexican plant was still in operation, and 'we are looking at it. We may get involved with it in the future, but right this second, we're not.' Feds: Minneapolis, Dakota County search warrants stemmed from 900 lbs of meth found in Burnsville storage unit Eagan city administrator withdraws resignation, passes up ICMA role Community memorial set for William 'Ike' Eickholt, found dead last winter MN Legislature: Measure to divert transportation funds from counties dropped Charges filed in drive-by shooting outside Burnsville High School graduation
Yahoo
a day ago
- Yahoo
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
Both Johnson & Johnson JNJ and Merck MRK are leading U.S. healthcare conglomerates — blue-chip pharmaceutical companies with massive R&D budgets and blockbuster drug portfolios. Both companies have a strong presence in oncology, immunology and neuroscience areas. Other than that, J&J also has drugs for cardiovascular and metabolic diseases, pulmonary arterial hypertension (PAH) and infectious diseases, along with a strong presence in the medical devices segment. On the other hand, Merck boasts a strong presence in vaccines, virology and hospital acute care. Both firms face looming patent expirations and headwinds from Medicare Part D redesign. But which one is a better investment option today? Let's take a closer look at their fundamentals, growth prospects and challenges to make an informed choice. J&J's biggest strength is its diversified business model, which helps it to withstand economic cycles more effectively. It operates through more than 275 subsidiaries. Its Innovative Medicine unit is showing a growth trend. The segment's sales rose 4.4% in the first quarter of 2025 on an organic basis despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. In 2025, J&J expects growth in the Innovative Medicine segment in the face of Stelara biosimilar entrants to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J also has an interesting R&D pipeline that can generate innovative products and further drive its growth. J&J has been on an acquisition spree lately, with the latest acquisition of Intra-Cellular Therapies strengthening its presence in the neurological and psychiatric drug market. Sales in J&J's MedTech business are facing continued headwinds in the Asia Pacific, specifically in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses. The company lost U.S. patent exclusivity of its blockbuster drug, Stelara, in 2025. The launch of generics is expected to significantly erode the drug's sales, hurting J&J's sales and profits in 2025. J&J also expects a negative impact of approximately $2 billion in sales due to the Medicare Part D redesign in 2025. The Part D redesign is expected to mainly hurt sales of drugs like Stelara, Tremfya, Erleada and PAH drugs J&J faces more than 62,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of its talc-based Johnson's Baby Powder. In April, a bankruptcy court in Texas rejected J&J's proposed bankruptcy plan to settle its talc lawsuits after a two-week trial in Houston. J&J will go back to the traditional tort system to fight the lawsuits individually with its bankruptcy strategy to settle the lawsuits failing for the third time. J&J's cash and cash equivalents were $38.8 billion at the end of March 2025 against long-term debt of $38.4 billion, resulting in a debt-to-capital ratio of 0.33, much lower than the industry's average of 0.42. Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Keytruda's sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects continued growth from Keytruda, particularly in early lung cancer. Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. Merck is working on different strategies to drive Keytruda's long-term growth. Merck has been making meaningful regulatory and pipeline progress across areas like oncology (mainly Keytruda), vaccines and infectious diseases while executing strategic business moves. Merck's phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. Merck's new products, Capvaxive and Winrevair, are witnessing strong launches and have the potential to generate significant revenues over the long term. Earlier this week, the FDA approved its respiratory syncytial virus (RSV) vaccine, Enflonsia (clesrovimab). However, sales of Gardasil, which is Merck's second-largest product, are declining due to a weak performance in China, which resulted from sluggish demand trends amid an economic slowdown. Merck is also seeing weakness in the diabetes franchise and the generic erosion of some drugs. Merck is heavily reliant on Keytruda. Though Keytruda may be Merck's biggest strength and a solid reason to own the stock, it can also be argued that the company is excessively dependent on the drug and it should look for ways to diversify its product lineup. There are rising concerns about the firm's ability to grow its non-oncology business ahead of the upcoming loss of exclusivity of Keytruda in 2028. Also, competitive pressure might increase for Keytruda in the near future. Medicare Part D redesign is expected to hurt sales of diabetes drugs, Januvia/Janumet, in 2025. At the end of March 2025, its cash and cash equivalents were $9.2 billion against long-term debt of $33.5 billion, resulting in a debt-to-capital ratio of 0.41, which is slightly lower than the industry average of 0.42. The Zacks Consensus Estimate for J&J's 2025 sales and EPS implies a year-over-year increase of 2.7% and 6.2%, respectively. The Zacks Consensus Estimate for 2025 earnings has risen from $10.54 per share to $10.60 over the past 60 days, while that for 2026 has declined from $11.02 to $10.98 over the same timeframe. Image Source: Zacks Investment Research The Zacks Consensus Estimate for MRK's 2025 sales and EPS implies a year-over-year increase of 0.9% and 16.6%, respectively. EPS estimates for both 2025 and 2026 have declined over the past 60 days. Image Source: Zacks Investment Research Year to date, J&J's stock has risen 10% compared with the industry's increase of 0.6%. Merck's stock has declined 17.5%. Image Source: Zacks Investment Research MRK looks more attractive than J&J from a valuation standpoint. Going by the price/earnings ratio, J&J's shares currently trade at 14.53 forward earnings, slightly lower than 15.23 for the industry and its 5-year mean of 15.77. Merck's shares currently trade at 8.76 forward earnings, significantly lower than the industry as well as the stock's 5-year mean of 12.88. Image Source: Zacks Investment Research J&J's dividend yield is 3.32%, while Merck's is slightly higher at 3.98%. Image Source: Zacks Investment Research Both Merck & J&J have a Zacks Rank #3 (Hold) each, which makes choosing one stock a difficult task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Merck has one of the world's best-selling drugs in its portfolio, generating billions of dollars in revenues. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. However, the company's problems are too many at present, including persistent challenges for Gardasil in China, potential competition for Keytruda and rising competitive and generic pressure on some drugs. All these factors have raised doubts about Merck's ability to navigate the Keytruda loss of exclusivity period successfully. Consistently declining estimates also reflect analysts' pessimistic outlook for the stock. On the other hand, J&J has shown steady revenue and EPS growth for years. J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half of 2025 than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps. J&J expects growth to accelerate from 2026 onward. Despite headwinds like softness in the MedTech unit, the legal battle surrounding its talc lawsuits, Stelara patent cliff and the potential impact of Part D redesign, J&J seems just one step ahead of Merck due to better prospects for sales and profit growth amid the various challenges. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
